Form 4: Fennec Pharmaceuticals CFO Robert Andrade Reports Share Release
SEC Form 4 Filing
Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares from restriction on April 30, 2024.
Summary
- Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, reported a transaction involving the company's common shares.
- On April 30, 2024, 1,042 common shares were released from restriction.
- These shares were originally awarded on March 31, 2023.
- Following this transaction, Andrade beneficially owns 105,313 common shares.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies. It provides transparency into the holdings and transactions of company executives.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 2023-03-31 | Date shares were originally awarded. |
| 2024-04-30 | Date of the share release transaction. |
| 2024-05-02 | Date of the report signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.